Patient Guide: A Phase III, Active-Controlled Study of SHR-A1811 Versus Trastuzumab Emtansine (T-DM1) in HER2-Positive Primary Breast Cancer Participants With Residual Invasive Disease Following Neoadjuvant Therapy

We'll Help You Connect with This Trial

Quri.ai is a free clinical trial matching service. We help patients like you connect directly with research sites conducting this study.

  • Get matched to the right study location for you
  • Connect directly with study coordinators at 2 participating sites
  • Understand eligibility with our simplified screening tool
  • Free service - we're here to help you access clinical research
Trial ID: NCTNCT06126640
Status: 🟢 Enrolling Now
Condition: HER2-Positive Primary Breast Cancer Participants With Residual Invasive Disease Following Neoadjuvant Therapy
Phase: PHASE3

Find a Study Location Near You

This study is available at 2 research sites. We'll help you connect with the location that's right for you.

Participating sites include:
  • Shanghai, Shanghai
  • Tianjin, Tianjin

Loading interactive enrollment tools...

The full interactive experience will load momentarily